Physician profile
Daniel D Washburn
NPI 1013901461
$1,122.54
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $217 · 2021: $299 · 2022: $296 · 2023: $108 · 2024: $13.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $122.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $620.33 | 2019-2024 | Ozempic, Rybelsus |
| Abbvie INC. | $160.77 | 2021-2022 | |
| Dexcom, INC. | $118.14 | 2020-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $57.65 | 2019-2023 | |
| Insulet Corporation | $31.51 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.39 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.93 | 2022 | |
| Horizon Therapeutics Plc | $19.37 | 2023 | Tepezza |
| Mylan Specialty L.P. | $17.24 | 2021 | |
| Medtronic, INC. | $14.26 | 2021 | |
| Lilly USA, LLC | $14.06 | 2019 | |
| Ascensia Diabetes Care US INC. | $13.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Washburn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.